Menu ×


Lassa Fever Treatment Market Segmentation by Symptoms (Seizures, Tremor, Coma, Nausea, Vomiting, and Others); by Treatment {Medication (Ribavirin, and Others), Supportive Care, and Others} – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Lassa Fever Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • June, 2021: Novartis AG to collaborate with Hewlett Packard Enterprise to address global health challenges. Novartis is the leading pharmaceutical company distributing drugs over the years.

  • February 11, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics.

Global Lassa Fever Treatment Market Highlights over 2022 – 2030

The global Lassa fever treatment market is estimated to grow at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of Lassa fever, especially in the Middle East and Africa region, backed by lack of sanitation and proper healthcare facilities in the region. The major cause of Lassa fever is consumption of food or water contaminated with rodent urine or faeces. According to the data by the UNICEF, 5 out of 10 people do not have access to safe sanitation services, in 2020. Moreover, growing cases of the fever across the world, is projected to promote the market growth. According to the data by the World Health Organization (WHO), 1 in every 5 Lassa fever infections result in severe infection in organs. Moreover, in 80% cases, no symptoms are reported. Symptoms can vary from mild symptoms, such as, nausea, and vomiting, to severe symptoms, such as, deafness, seizure, and coma. As per another report by the WHO, deafness occurs in 25% of the cases of Lassa fever.

Lassa Fever Treatment Market Graph

The market is segmented by treatment into medication, supportive care, and others, out of which, the medication segment is anticipated to hold the largest share in the global Lassa fever treatment market over the forecast period on account of fast relief action of the drugs, quicker symptom elevation, and easy availability in pharmacies.

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years. CLICK TO DOWNLOAD SAMPLE REPORT

Global Lassa Fever Treatment Market Regional Synopsis

On the basis of geographical analysis, the global Lassa fever treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of increasing incidences of Lassa fever in the region. Lack of proper sanitation services in the region is also expected to significantly fuel the regional market growth. According to the statistics by the WHO, around 2 billion people do not have basic sanitation facilities, such as, toilets, especially in middle and low-income economies. Improving healthcare facilities, backed by increasing investment in the sector is further estimated to boost the market growth. According to the data by the World Bank, USD 520.89 were spent per capita on healthcare in the Middle East and North Africa region, in 2018.

Health Expenditure per Capita (Current USD), Middle East imageThe market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the presence of major pharmaceutical companies in the region, along with high investment for research and development of new drugs.

Lassa Fever Treatment Market Share image

The global Lassa fever treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global Lassa fever treatment market includes the following segments:

By Symptoms

  • Seizures
  • Tremor
  • Coma
  • Nausea
  • Vomiting 
  • Others

By Treatment

  • Medications
    • Ribavirin
    • Others
  • Supportive Care
  • Others

Growth Drivers

  • Growing Incidences of Lassa Fever
  • Increasing Investment to Improve Healthcare Sector in Underdeveloped Economies


  • Lack of Awareness Amongst People

Top Featured Companies Dominating the Market

  • Pfizer, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Novartis International AG
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Abbott Laboratories
  • Cipla Limited


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved